Eyenovia, Inc. (EYEN)
| Market Cap | 129.27M |
| Revenue (ttm) | 2.00M |
| Net Income (ttm) | -19.77M |
| Shares Out | 25.62M |
| EPS (ttm) | -0.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $5.05 |
| Previous Close | $5.38 |
| Change ($) | -0.34 |
| Change (%) | -6.23% |
| Day's Open | 5.41 |
| Day's Range | 5.03 - 5.42 |
| Day's Volume | 66,758 |
| 52-Week Range | 2.55 - 7.72 |
NEW YORK--(BUSINESS WIRE)-- #EYEN--Dr. Julia Haller brings experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader to her role as an Eyenovia director.
Announces MydCombi expected PDUFA date of October 28, 2021
NEW YORK & CHICAGO--(BUSINESS WIRE)-- #MydCombi--Eyenovia has tapped EVERSANA as exclusive distributor of its MydCombi product for pupil dilation in the U.S., pending the product's FDA approval.
NEW YORK--(BUSINESS WIRE)-- #Optejet--Eyenovia's MAP™ fixed-combination pharmaceutical for pupil dilation has been shown to be safe, effective and superior in comparative study.
NEW YORK--(BUSINESS WIRE)-- #mydriasis--FDA accepts Eyenovia's NDA for MydCombi, a unique fixed combination pupil dilation agent delivered with the Optejet. PDUFA date is expected 4Q 2021.
The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET The webinar, “Presbyopia in Focus: Unlocking On...
NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia consultant Dr. David Wirta will speak at the Ophthalmology Innovation Summit Presbyopia Innovation Showcase on January 28.
Today, we revisit a promising small ocular biopharma concern called Eyenovia for the first time in almost 18 months. The company continues to advance its pipeline and recently submitted a marketing appl...
NEW YORK--(BUSINESS WIRE)-- #FDA--Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.
NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia has enrolled its first patients in the Phase 3 VISION-1 Study of MicroLine for the improvement in near vision in patients with presbyopia.
NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia obtains FDA acceptance of its IND application for MicroLine, a therapy designed for improvement in near vision in patients with presbyopia.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.
Company reaffirms near term milestones for the Mydcombi™ (MicroStat) NDA and the MicroLine presbyopia program Phase III results
One year ago, I recommended Eyenovia's stock based on the company's effort in addressing several ophthalmic needs. Since that time, the stock has stagnated yet two collaborations have been announced.
LAVAL, QC and NEW YORK, Oct. 12, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, its leading global eye health business, and Eyenovia, Inc., (NASDAQ: ...
NEW YORK--(BUSINESS WIRE)-- #AAOPT--Drs. Siddarth Rathi, April Jasper to present latest analyses and updates from Eyenovia's clinical studies at the American Academy of Optometry 2020
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...
NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...
NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2020 Results - Earnings Call Transcript
Eyenovia (EYEN) is in the news Tuesday after an exclusive deal with Arctic Vision for two of its treatments sent EYEN stock soaring higher. The post Eyenovia News: Why EYEN Stock Is Skyrocketing 33% Tod...
Eyenovia Inc. (NASDAQ: EYEN) shares soared on Tuesday after the company announced an exclusive license agreement with Artic Vision to develop and commercialize its MicroPine for the treatment of progres...
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, tod...
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented p...
NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented ...
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2020 Results - Earnings Call Transcript
NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented p...
As of late, it has definitely been a great time to be an investor Eyenovia
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2019 Results - Earnings Call Transcript
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented p...
NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented ...
As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).
Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2019 Results - Earnings Call Transcript
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
Defers development activities of MicroProst and MicroTears
Eyenovia is a specialty ophthalmic company targeting several ophthalmic needs, including progressive myopia and presbyopia.
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented ...
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
Today, we take an in-depth look at a microcap 'Busted IPO' named Eyenovia.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2019 - Earnings Call Transcript
CEO of Eyenovia Inc (30-Year Financial, Insider Trades) Tsontcho Ianchulev (insider trades) bought 233,813 shares of EYEN on 07/11/2019 at an average price of $2.78 a share.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2019 Results - Earnings Call Transcript
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2018 Results - Earnings Call Transcript
About EYEN
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print (MAP) platform technology. The company focuses on to develop clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its pipelines focus on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceut... [Read more...]
| Industry Biotechnology | IPO Date Jan 25, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol EYEN |
Analyst Forecasts
According to 3 analysts, the average rating for Eyenovia stock is "Buy." The 12-month stock price forecast is 12.50, which is an increase of 147.77% from the latest price.